Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0003
Investigational/discontinued oncology
17-AAG / Tanespimycin
Senolytic / HSP90
Preclinical senolytic and oncology research activity
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- HSP90 inhibition
- Primary market use
- Senolytic / oncology research
Pharmacology
- Molecular weight (Da)
- 585.69
- Oral bioavailability
- Low/poor; IV formulations studied
- Half-life
- ~2-4 h
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational/discontinued oncology
- Value-for-money score
- 2 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
HSP90 inhibitor; practical value limited by formulation and toxicity